PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 236
- Registration Number
- NCT04218084
- Locations
- 🇪🇬
Ain Shams University Hospital-Clinical Research Center (MASRI), Cairo, Egypt
🇬🇭Department of Child Health, University of Ghana Medical School, College of Health Sciences, Accra, Ghana
🇮🇹Azienda Ospedaliera Universitaria (AOU) Meyer, Firenze, Italy
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: PF-06826647 300 mg QDDrug: PlaceboDrug: PF-06826647 100 mg QDDrug: PF-06826647 600 mg QDDrug: PF-6826647 400 mg QD
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04209556
- Locations
- 🇺🇸
ADVA Clinical Research, Inglewood, California, United States
🇺🇸Hope Clinical Research, Canoga Park, California, United States
🇺🇸Gastroenterology Consultants P.C., Roswell, Georgia, United States
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
- Conditions
- Community Acquired PneumoniaComplicated Skin and Soft Tissue Infection
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 317
- Registration Number
- NCT04198571
- Locations
- 🇪🇸
Hospital Universitario Valle de Hebrón, Barcelona, Spain
🇪🇸Hospital Ramon y Cajal, Madrid, Spain
🇨🇴Centro médico Imbanaco, Cali, Colombia
The Effectiveness and Safety of Apixaban in NVAF Patients With History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT04198844
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
- Conditions
- Hepatic ImpairmentHealthy Participants
- Interventions
- Drug: PF-06835919 25 mg
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT04193436
- Locations
- 🇨🇿
Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
🇸🇰Summit Clinical Research, s.r.o.,, Bratislava, Slovakia
🇧🇪Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Open-Label Extension of Voxelotor
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 162
- Registration Number
- NCT04188509
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Healthcare of Atlanta Scottish Rite, Atlanta, Georgia, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Safety and Efficacy of Trastuzumab BS
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT04181333
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
- Conditions
- Non-small-cell Lung CancerAdvanced Malignancies
- Interventions
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 155
- Registration Number
- NCT04181788
- Locations
- 🇨🇳
Beijing Cancer hospital, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 813
- Registration Number
- NCT04176354
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 102
- Registration Number
- NCT04175262
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada